This activity was funded by Alnylam Pharmaceuticals. The medical content was developed independently by M3 and Professor Violaine Planté-Bordeneuve.
Transthyretin-mediated (ATTR) amyloidosis
3-year acoramidis (AG10) results in ATTR-CM: data from an ongoing OLE
The benefits of tafamidis: is there an age limit?
Vutrisiran efficacy and safety at 18 months: results from the HELIOS-A phase III trial
Managing complications in ATTR-CM
Gene silencing therapies for hereditary ATTR amyloidosis: what do we know and what can we expect?
Top image: Design Cells
The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.
References: 1. xxxx; 2. xxx
Doctors.net.uk and are not responsible for content hosted on third party websites.
You will be directed to:
Doctors.net.uk is not responsible for content hosted on third party websites.